Clene Reports Q3 2026 Financials, NDA Filing for ALS Drug
Clene submitted an FDA NDA for ALS drug CNM-Au8 and expects cash runway to improve by leveraging capital from a 2026 financing, signaling progress for this clinical-stage biopharmaceutical company.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed